115 related articles for article (PubMed ID: 34006465)
1. Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier.
Chung WP; Yang CT; Chen HY; Su CY; Su HW; Ou HT
J Formos Med Assoc; 2022 Jan; 121(1 Pt 2):319-328. PubMed ID: 34006465
[TBL] [Abstract][Full Text] [Related]
2. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
3. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.
Hsu JY; Chang CJ; Cheng JS
Sci Rep; 2022 Jan; 12(1):729. PubMed ID: 35031634
[TBL] [Abstract][Full Text] [Related]
4. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
Celik A; Berg T; Jensen MB; Jakobsen E; Nielsen HM; Kümler I; Glavicic V; Jensen JD; Knoop A
Breast Cancer (Auckl); 2023; 17():11782234231203292. PubMed ID: 37810797
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
Du F; Yuan P; Luo Y; Wang J; Ma F; Cai R; Fan Y; Li Q; Zhang P; Xu B
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):788-92. PubMed ID: 26813602
[TBL] [Abstract][Full Text] [Related]
7. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice.
O'Shaughnessy J; Emens LA; Chui SY; Wang W; Russell K; Lin SW; Flores Avile C; Luhn P; Schneeweiss A
Curr Oncol; 2021 Jul; 28(4):2741-2752. PubMed ID: 34287291
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
Kimura T; Takami T; Piao Y; Ntalla I; Saji S
Breast Cancer Res Treat; 2024 Jul; 206(1):91-103. PubMed ID: 38704772
[TBL] [Abstract][Full Text] [Related]
9. Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices.
Tan R; Cassoli L; Yan Y; Shen V; Day BM; Mitchell EP
Front Public Health; 2022; 10():859113. PubMed ID: 35685754
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer.
Ghebeh H; Elshenawy MA; AlSayed AD; Al-Tweigeri T
Immunotherapy; 2022 Mar; 14(4):189-199. PubMed ID: 34984928
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
12. Objective response of first-line chemotherapy of triple-negative breast cancer translates into survival benefit: an analysis in an independent, prospective clinical trial and a real-world setting.
Li T; Zhu YH; Zhang J; Wang BY; Zhang S; Wang LP; Cao J; Tao ZH; Xie J; Hu XC
Neoplasma; 2020 Nov; 67(6):1400-1408. PubMed ID: 32657608
[TBL] [Abstract][Full Text] [Related]
13. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.
Kim H; Kim HJ; Kim H; Kim HR; Jo H; Hong J; Kim R; Kim JY; Ahn JS; Im YH; Lee SK; Kim H; Shin SY; Park YH
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830990
[TBL] [Abstract][Full Text] [Related]
14. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
Cabel L; Carton M; Pistilli B; Dalenc F; Vanlemnens L; Levy C; Jacot W; Debled M; Loeb A; Hennequin A; De la Motte Rouge T; Laborde L; Laurent C; Chamorey E; Parent D; Petit T; Mouret-Reynier MA; Campone M; Perrocheau G; Labreveux C; Bachelot T; Robain M; Lerebours F
Breast; 2021 Apr; 56():18-25. PubMed ID: 33561617
[TBL] [Abstract][Full Text] [Related]
15. Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy.
Chen Y; Zhang J; Hu XC; Wang BY; Wang ZH; Wang LP; Cao J; Tao ZH; Du YQ; Zhao YN; Gong CC; Jin J
Ann Palliat Med; 2020 Sep; 9(5):3018-3027. PubMed ID: 32787354
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Lu F; Hou Y; Chen Z; Jiang J; He X; Xia Y; Cao K; Chang L; Li W
Technol Cancer Res Treat; 2021; 20():15330338211016369. PubMed ID: 33977814
[TBL] [Abstract][Full Text] [Related]
17. Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
Srimuninnimit V; Pornpraserthsuk P; Chaiwerawattana A; Kongdan Y; Namkanisorn T; Somwangprasert A; Jatuparisuthi C; Puttawibul P; Vongsaisuwan M; Thongthieang L; Bandidwattanawong C; Tantimongkolsuk C
PLoS One; 2018; 13(12):e0209040. PubMed ID: 30566471
[TBL] [Abstract][Full Text] [Related]
18. Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer.
Collier KA; Asad S; Tallman D; Jenison J; Rajkovic A; Mardis ER; Parsons HA; Tolaney SM; Winer EP; Lin NU; Ha G; Adalsteinsson VA; Stover DG
JCO Precis Oncol; 2021; 5():. PubMed ID: 34849445
[TBL] [Abstract][Full Text] [Related]
19. Single agent versus combination chemotherapy for metastatic breast cancer.
Carrick S; Parker S; Wilcken N; Ghersi D; Marzo M; Simes J
Cochrane Database Syst Rev; 2005 Apr; (2):CD003372. PubMed ID: 15846660
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer.
Luhn P; Chui SY; Hsieh AF; Yi J; Mecke A; Bajaj PS; Hasnain W; Falgas A; Ton TG; Kurian AW
J Comp Eff Res; 2019 Oct; 8(14):1173-1185. PubMed ID: 31394922
[No Abstract] [Full Text] [Related]
[Next] [New Search]
